Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | NAAA | Q02083 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | AGXT | P21549 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | CA7 | P43166 | 2/20 | 0.39 |
| ▸ | CA9 | Q16790 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23567237 | 0.90 | TSHR (0.50) | TSHRNAAAMEN1KMT2AIDO1 | |
| SCHEMBL1603273 | 0.88 | TSHR (0.52) | TSHRNAAAIDO1LTA4HTDP1 | |
| SCHEMBL3376445 | 0.86 | TSHR (0.50) | TSHRNAAALTA4HTDP1L3MBTL1 | |
| SCHEMBL19608820 | 0.85 | L3MBTL1 (0.50) | TSHRNAAATDP1L3MBTL1HRH4 | |
| SCHEMBL1422059 | 0.85 | L3MBTL1 (0.50) | TSHRNAAATDP1L3MBTL1HRH4 | |
| SCHEMBL23014897 | 0.85 | L3MBTL1 (0.50) | TSHRNAAATDP1L3MBTL1HRH4 | |
| SCHEMBL1421766 | 0.85 | L3MBTL1 (0.50) | TSHRNAAATDP1L3MBTL1HRH4 | |
| SCHEMBL3821073 | 0.82 | TSHR (0.54) | TSHRNAAAIDO1LTA4HTDP1 | |
| SCHEMBL20423790 | 0.80 | NAAA (0.53) | TSHRNAAAIDO1LTA4HTDP1 | |
| SCHEMBL23567268 | 0.80 | TSHR (0.47) | TSHRNAAAIDO1TDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022036040-A1 | SYNTHESIS OF SMALL MOLECULES INSPIRED BY PHOMOXANTHONE A | WORCESTER POLYTECHNIC INSTITUTE (US) | 2022-02-17 | — | — | WO | disclosed |
| US-11046680-B1 | Heteroaryl-substituted triazoles as APJ receptor agonists | AMGEN INC. (US) | 2021-06-29 | — | — | US | disclosed |
| US-11046680-B1 | Heteroaryl-substituted triazoles as APJ receptor agonists | AMGEN INC. (US) | 2021-06-29 | — | — | US | disclosed |
| CN-109563082-B | Nuclear magnetic resonance imaging compound, intermediate thereof, nuclear magnetic resonance imaging agent and application thereof, and nuclear magnetic resonance imaging method | 北京市神经外科研究所 | 2021-03-30 | — | — | CN | disclosed |
| EP-3541805-B1 | HETEROARYL-SUBSTITUTED TRIAZOLES AS APJ RECEPTOR AGONISTS | AMGEN INC (US) | 2020-10-14 | — | — | EP | disclosed |
| US-10647731-B2 | Thiazolopyrimidinones and methods of use thereof | GENENTECH, INC. (US) | 2020-05-12 | — | — | US | disclosed |
| US-10647731-B2 | Thiazolopyrimidinones and methods of use thereof | GENENTECH, INC. (US) | 2020-05-12 | — | — | US | disclosed |
| EP-3541805-A1 | HETEROARYL-SUBSTITUTED TRIAZOLES AS APJ RECEPTOR AGONISTS | Amgen Inc. (US) | 2019-09-25 | — | — | EP | disclosed |
| EP-3415519-A1 | THIAZOLOPYRIMIDINONES AS MODULATORS OF NMDA RECEPTOR ACTIVITY | F. Hoffmann-La Roche AG (CH) | 2018-12-19 | — | — | EP | disclosed |
| US-20180244694-A1 | THIAZOLOPYRIMIDINONES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2018-08-30 | — | — | US | disclosed |
| US-20110251178-A1 | Bicyclic Pyridinylpyrazoles | BAYER CROPSCIENCE AG (DE) | 2011-10-13 | — | — | US | disclosed |
| WO-2008149053-A1 | BICYCL0 [2. 2. 1] HE PT- 2-YLAMINE DERIVATES AND THEIR USE | ARGENTA DISCOVERY LTD. (GB) | 2008-12-11 | — | — | WO | disclosed |
| US-7125999-B2 | Process for producing organotitanium compound and process for addition reaction | NISSAN CHEMICAL INDUSTIES, LTD. (JP) | 2006-10-24 | — | — | US | disclosed |
| US-20040167344-A1 | Process for producing organotitanium compound and process for addition reaction | FUMIE SATO | 2004-08-26 | — | — | US | disclosed |
| US-6743916-B2 | REACTING AN ACETYLENE COMPOUND IN THE PRESENCE OF A TITANIUM COMPOUND AND GRIGNARD REAGENT TO OBTAIN ORGANOTITANIUM COMPOUND | Sato, Fumie (JP) | 2004-06-01 | — | — | US | disclosed |
| US-6630484-B1 | 6-and 7-substituted analogs of swainsonine their preparation and therapeutic use | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2003-10-07 | — | — | US | disclosed |
| US-20030096996-A1 | Process for producing organotitanium compound and process for addition reaction | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2003-05-22 | — | — | US | disclosed |
| EP-0934317-A2 | NOVEL 6 OR 7 SUBSTITUTED ANALOGUES OF SWAINSONINE, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS THERAPEUTIC AGENTS | Glycodesign Inc. (CA) | 1999-08-11 | — | — | EP | disclosed |
| WO-1998014445-A2 | NOVEL 6 OR 7 SUBSTITUTED ANALOGUES OF SWAINSONINE, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS THERAPEUTIC AGENTS | GLYCODESIGN INC. (CA) | 1998-04-09 | — | — | WO | disclosed |
| US-4477673-A | Process for the preparation of substituted divinylpyridines and novel substituted divinylpyridines | CIBA-GEIGY CORPORATION (US) | 1984-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167344-A1 | Process for producing organotitanium compound and process for addition reaction | ZYX, H1-4, GRIA4 | TSHR 465/4885NAAA 3633/4885MEN1 1460/4885 |
| US-10647731-B2 | Thiazolopyrimidinones and methods of use thereof | TPMT, THPO, CYP11B2 | TSHR 614/4885NAAA 3795/4885MEN1 1268/4885 |
| US-11046680-B1 | Heteroaryl-substituted triazoles as APJ receptor agonists | AGTR1, AGTR2, TBXA2R | TSHR 254/4885NAAA 3557/4885MEN1 4391/4885 |
| US-20110251178-A1 | Bicyclic Pyridinylpyrazoles | PLPBP, PNPO, PIR | TSHR 3280/4885NAAA 883/4885MEN1 1343/4885 |
| US-20180244694-A1 | THIAZOLOPYRIMIDINONES AND METHODS OF USE THEREOF | TPMT, THPO, CYP11B2 | TSHR 614/4885NAAA 3795/4885MEN1 1268/4885 |
| US-20030096996-A1 | Process for producing organotitanium compound and process for addition reaction | ZYX, H1-4, GRIA4 | TSHR 465/4885NAAA 3633/4885MEN1 1460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.